Novus Diagnostics is developing a sample-to-answer sepsis diagnostic device that utilizes patented microfluidic electrochemical sensors and advanced diagnostic algorithms to deliver accurate results within 15 minutes. This rapid bedside test enables clinicians to confirm infections and classify pathogens, facilitating immediate targeted treatment during critical early stages of sepsis.
Funding
$9.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Sepsis, a bloodstream infection, requires rapid diagnosis and targeted treatment to improve patient outcomes, as delays can be fatal. Traditional sepsis diagnosis often involves lengthy lab procedures, hindering timely clinical decision-making during the critical early stages of the condition.
Solution
Novus Diagnostics offers a rapid, point-of-care diagnostic solution for sepsis that delivers accurate results in 15 minutes. The SepTec™ platform utilizes patented microfluidic electrochemical sensors and advanced diagnostic algorithms to simultaneously diagnose infection and classify the causative pathogen (Gram-negative, Gram-positive, or fungal). This enables clinicians to confirm infections and initiate targeted treatment during the critical early stages of sepsis, directly at the patient's bedside.
Target Audience
The primary target audience includes clinicians and healthcare providers in acute care settings, such as hospitals and emergency departments, who require rapid and accurate sepsis diagnosis to facilitate timely treatment decisions.
Features
- Sample-to-answer sepsis diagnostic device providing results in 15 minutes
- Patented microfluidic electrochemical sensors for pathogen detection
- Advanced diagnostic algorithms for accurate result interpretation
- Simultaneous diagnosis of infection and classification of the causative pathogen (Gram-negative, Gram-positive, or fungal)
- Point-of-care testing, enabling rapid bedside assessment